Richard W. Paul & Associates’s Aquestive Therapeutics AQST Stock Holding History

Richard W. Paul & Associates’s Portfolio AQST Stock Details AQST Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q1	–	Sell	-1,602	Closed	-$5.7K	–	342
2024 Q4	$5.7K	Buy	1,602 +130	+9%	+$599	﹤0.01%	346
2024 Q3	$7.33K	Hold	1,472	–	–	﹤0.01%	329
2024 Q2	$3.83K	Hold	1,472	–	–	﹤0.01%	357
2024 Q1	$6.27K	Buy	1,472 +49	+3%	+$163	﹤0.01%	344
2023 Q4	$2.88K	Hold	1,423	–	–	﹤0.01%	387
2023 Q3	$2.18K	Hold	1,423	–	–	﹤0.01%	393
2023 Q2	$2.35K	Hold	1,423	–	–	﹤0.01%	418
2023 Q1	$1.62K	Hold	1,423	–	–	﹤0.01%	454
2022 Q4	$1.28K	Buy	+1,423	New	+$1.34K	﹤0.01%	453

Other funds holding AQST

BCM

Bratton Capital Management Fort Worth, Texas $40.7M AUM 43.1% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

PFCS

Pale Fire Capital SE Prague, Czech Republic $1.14B AUM 42.87% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

Janney Montgomery Scott Philadelphia, Pennsylvania $40.4B AUM 21.2% 1-Year Est. Return

Richard W. Paul & Associates's AQST Position: Q1 2025 in Review

Richard W. Paul & Associates sold out of Aquestive Therapeutics (AQST) in Q1 2025, closing a stake of 1,602 shares — an estimated $5.7K sold.

Richard W. Paul & Associates first reported a position in AQST in Q4 2022 and held it in 9 quarters. The position peaked at $7.33K in Q3 2024. 121 funds tracked by Wall St. Rank hold AQST as of Q1 2025.

Richard W. Paul & Associates reported no remaining Aquestive Therapeutics position as of Q1 2025 after selling out during the quarter.
Richard W. Paul & Associates sold 1,602 Aquestive Therapeutics shares in Q1 2025, an estimated $5.7K.
Richard W. Paul & Associates first reported a position in Aquestive Therapeutics in Q4 2022 and held it in 9 quarters.
Richard W. Paul & Associates's Aquestive Therapeutics position peaked at $7.33K in Q3 2024.
121 funds tracked by Wall St. Rank held Aquestive Therapeutics as of Q1 2025.

Based on Richard W. Paul & Associates's 13F filing for Q1 2025, filed 12 May 2025.